Japanese Journal of Clinical Oncology Advance Access published online on June 1, 2009
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyp050
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author (2009). Published by Oxford University Press. All rights reserved
Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients
1 Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Ehime
2 Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan
For reprints and all correspondence: Naruto Taira, Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, 2-5-1 Shikata, Okayama 700-8558, Japan. E-mail: ntaira{at}md.okayama-u.ac.jp
Received March 17, 2009; accepted April 25, 2009
Objective: The 7-year follow-up of the US oncology 9735 trial demonstrated the superiority of TC [docetaxel (DTX)/cyclophosphamide (CPA)] to doxorubicin/CPA therapy. To introduce TC therapy in Japan, the verification of the safety and tolerability is essential. We performed a collaborative prospective safety study with Okayama University to introduce TC therapy.
Methods: The subjects were 53 patients aged from 33 to 67 years at intermediate risk based on the St Gallen risk classification who underwent radical surgery for primary breast cancer between August 2007 and December 2008. As post-operative adjuvant chemotherapy, four cycles of TC (DTX 75 mg/m2 + CPA 600 mg/m2) were administered at 3-week intervals. Adverse events were evaluated based on National Cancer Institute—Common Terminology Criteria for Adverse Events ver. 3.0. The safety and completion rate were evaluated as the primary and secondary endpoints, respectively.
Results: Regarding hematological toxicity, Grade (G) 4 neutropenia occurred in 71.7% and G3 in 26.4%. G3–4 leukopenia developed in 32.1% and 56.6%, respectively, G4 anemia in 1.9% and G1–2 anemia in 26.4%. Regarding non-hematological toxicity, systemic malaise, skin eruption, edema, myalgia, arthralgia and nausea were noted in most patients. The completion rate was 94.3%, dose reduction was necessary in 7.5% and granulocyte colony-stimulating factor (G-CSF) support was required in 17.0%. On comparison between patients aged 65 years or older and younger than 65 years, the completion rate, dose reduction and incidence of febrile neutropenia (FN) were higher in the elderly patients. G-CSF support was more often needed in this subgroup.
Conclusions: TC therapy is tolerable for Japanese patients, but attention should be paid to the development of FN and neutropenia. The completion rate was lower in the elderly patients, showing that tolerability was not necessarily favorable.
Key Words: breast cancer • docetaxel • cyclophosphamide • adjuvant therapy • safety